Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Business Wire December 3, 2018

Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma

Business Wire December 2, 2018

The Global Cancer Therapy Market is set to Grow on the Wide use of Chemotherapy

PR Newswire November 28, 2018

China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection

Business Wire November 18, 2018

Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27

Business Wire November 12, 2018

Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

Business Wire November 9, 2018

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018

Business Wire November 9, 2018

Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018

Business Wire November 9, 2018

Investor Movement Index October Summary

Benzinga.com  November 6, 2018

Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018

Business Wire November 1, 2018

Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies

Business Wire October 31, 2018

Investor Expectations to Drive Momentum within Gilead Sciences, SCANA, Brink's, Fortive, Asbury Automotive Group, and Helmerich & Payne — Discovering Underlying Factors of Influence

GlobeNewswire October 31, 2018

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Business Wire October 30, 2018

The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Benzinga.com  October 26, 2018

Gilead Sciences Announces Fourth Quarter 2018 Dividend

Business Wire October 25, 2018

Gilead Sciences Announces Third Quarter 2018 Financial Results

Business Wire October 25, 2018

Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet

Business Wire October 22, 2018

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting

Business Wire October 20, 2018

Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018

Business Wire October 11, 2018

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018

Business Wire October 11, 2018